Used primarily in the treatment of colorectal cancer, this compound acts as a prodrug that is metabolized into 5-fluorouracil (5-FU), a potent antimetabolite that interferes with DNA and RNA synthesis in cancer cells. It is particularly utilized in adjuvant therapy following surgical resection of colorectal tumors, helping to reduce the risk of recurrence. Due to its ability to cross the blood-brain barrier, it has also been investigated for use in treating brain tumors. Oral administration offers convenience and sustained release, making it suitable for long-term treatment regimens. It is sometimes preferred in certain regions for its improved pharmacokinetic profile and reduced side effects compared to intravenous 5-FU.